What is the supply-demand outlook for nevirapine API given Huahai's FDA certification and global competition?

What is the supply-demand outlook for nevirapine API given Huahai's FDA certification and global competition?
Huahai Pharmaceutical's nevirapine tablets passed FDA inspection with zero deficiencies in 2007, marking the first Chinese-made formulation to enter the US market and establishing a quality benchmark for domestic production. This certification gave Huahai a competitive edge in exporting nevirapine API and finished dosage forms, though the company's recent financial reports show pressure from centralized procurement price cuts and US tariff hikes on pharmaceutical ingredients, including a 145% tariff on certain APIs in 2025. While nevirapine demand in developed markets is declining due to newer ARVs, emerging markets and China's free treatment program sustain baseline volumes. Huahai's integrated API-to-formulation strategy helps maintain margins, but the company is diverting R&D investment toward innovative drugs, suggesting nevirapine is now a mature, low-growth product in its portfolio.